Table 2.
Variable | PathCR | No PathCR | Chi-Sq | p |
---|---|---|---|---|
ER |
|
|
0.833 |
0.3613 |
Negative |
7 (35.0%) |
5 (25.0%) |
|
|
Positive |
3 (15.0%) |
5 (25.0%) |
|
|
PR |
|
|
5.000 |
0.0253 |
Negative |
10 (50.0%) |
6 (30.0%) |
|
|
Positive |
0 (0.0%) |
4 (20.0%) |
|
|
Run-in Treatment |
|
|
1.308 |
0.2528 |
Nab-paclitaxel |
7 (30.4%) |
3 (13.1%) |
|
|
Trastuzumab | 6 (26.1%) | 7 (30.4%) |